All In Biotech

Drug Trial Radar · NCT04916470

Research Study to Look at How Well Semaglutide Works in People Living With Heart Failure, Obesity and Type 2 Diabetes

Effect of Semaglutide 2.4 mg Once-weekly on Function and Symptoms in Subjects With Obesity-related Heart Failure With Preserved Ejection Fraction, and Type 2 Diabetes

Last checked: Nov 20, 2026Latest source record: Nov 2, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 617 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

617

Actual

Start

Jun 15, 2021

Primary completion

Oct 11, 2023

Study completion Oct 11, 2023

Sponsor

Lead sponsor
Novo Nordisk A/SNovo Nordisk (NVO)
Sponsor type
Industry
First posted
Jun 7, 2021

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study will look at how participants' daily life is affected by their heart failure. The study will also look at the change in participants' body weight. This study will compare the effect of semaglutide (a new medicine) compared to "dummy" medicine on body weight and heart failure symptoms. Participants will either get semaglutide or "dummy" medicine, which treatment participants get is decided by chance. Participants will need to take 1 injection once a week. The study medicine is injected with a thin needle in a skin fold in the stomach area, thigh or upper arm. During the study participants will have talks with the study staff about healthy lifestyle and physical activity. The study will last for about 59 weeks, that is a little more than 1 year. Participants will have 12 clinic visits with the study doctor. * At 6 of the visits participants will have blood samples taken. * At 5 of the visits participants will be asked to fill in a questionnaire * At 4 of the visits participants will have to do a 6-minute walking test * At 3 of the visits participants will have a test to check the heart. * participants will have their eyes checked before or at the start of the study and at the end of the study Women cannot take part if pregnant, breast-feeding or plan to become pregnant during the study period.

Conditions

  • Heart Failure With Preserved Ejection Fraction (HFpEF) and Diabetes Mellitus, Type 2

Interventions

  • SemaglutideDrug

    Participants will receive semaglutide subcutaneous (s.c.; under the skin) injection(s) once-weekly for 52 weeks. Dose will be gradually increased to 2.4 mg: 0.25 mg from week 1 to 4, 0.5 mg from week 5 to 8, 1.0 mg from week 9 to 12, 1.7 mg from week 13 to 16 and 2.4 mg from week 17 to week 52.

  • Placebo (Semaglutide)Drug

    Participants will receive semaglutide matching placebo s.c. injection(s) once-weekly for 52 weeks.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change in KCCQ (Kansas City Cardiomyopathy Questionnaire) Clinical Summary ScoreTime frame: Baseline (week 0), end of treatment (week 52)
  2. Percentage Change in Body WeightTime frame: Baseline (week 0), end of treatment (week 52)

Locations

180 sites in 16 countries. Site status is shown where the registry gives one.

  • Eastern Shore Rsrch Inst, LLC

    Fairhope, Alabama

  • Mobile Heart Specialists

    Mobile, Alabama

  • National Heart Institute Cal

    Beverly Hills, California

  • John Muir Physicians Network

    Concord, California

  • Valley Clinical Trials

    Covina, California

  • Keck Medical Center of USC - Outpatient Clinic

    Los Angeles, California

  • Valley Clinical Trials, Inc.

    Northridge, California

  • Lundquist Inst-Biomed Innovtn

    Torrance, California

  • OptumCare Clinical Trials LLC

    Golden, Colorado

  • Excel Med Ctr Clinical Trials

    Boca Raton, Florida

  • Bay Area Cardiology Associates, P.A.

    Brandon, Florida

  • Baptist Heart Specialists_Jacksonville

    Jacksonville, Florida

  • CV Res Ctr of S Florida

    Miami, Florida

  • Endeavor Health Clinical Operations-NCH

    Arlington Heights, Illinois

  • Endeavor Health Glenbook Hosp

    Evanston, Illinois

  • Northwestern University_Chicago_0

    Evanston, Illinois

  • Chicago Medical Research LLC

    Hazel Crest, Illinois

  • Deaconess Specialty Physicians

    Evansville, Indiana

  • Ascension St. Vincent Medical Group

    Indianapolis, Indiana

  • Cardiovascular Rsrch of NW_IN

    Munster, Indiana

  • Cotton-O'Neil Heart Center

    Topeka, Kansas

  • Baptist Health Woodland

    Elizabethtown, Kentucky

  • The Research Group of Lexington LLC

    Lexington, Kentucky

  • Baptist Health Louisville

    Louisville, Kentucky

  • Grace Research, LLC

    Bossier City, Louisiana

  • Heart Clinic of Hammond

    Hammond, Louisiana

  • Clinical Trials of Ame, LLC

    Monroe, Louisiana

  • Grace Research, LLC_Shreveport

    Shreveport, Louisiana

  • Louisiana Heart Center_Slidell

    Slidell, Louisiana

  • Ascension Saint Agnes Heart Ca

    Baltimore, Maryland

  • MedStar Good Samaritan Hosp

    Baltimore, Maryland

  • John Hopkins Hospital

    Baltimore, Maryland

  • Elite Research Center

    Flint, Michigan

  • Mayo Clinic

    Rochester, Minnesota

  • Univ of Mississippi Med Ctr

    Jackson, Mississippi

  • Saint Luke's Hospital of Kansas City

    Kansas City, Missouri

  • St Louis Heart & Vascular, P.C.

    St Louis, Missouri

  • Bryan Heart

    Lincoln, Nebraska

  • CHI Health Clinic Cardiology (CUMC - Bergan Mercy)

    Omaha, Nebraska

  • St Francis Hospital Lindner Research Center

    Greenvale, New York

Showing 40 of 180 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.